EP0894003A1 - Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep - Google Patents

Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep

Info

Publication number
EP0894003A1
EP0894003A1 EP97917889A EP97917889A EP0894003A1 EP 0894003 A1 EP0894003 A1 EP 0894003A1 EP 97917889 A EP97917889 A EP 97917889A EP 97917889 A EP97917889 A EP 97917889A EP 0894003 A1 EP0894003 A1 EP 0894003A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
aryl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97917889A
Other languages
German (de)
English (en)
Other versions
EP0894003A4 (fr
Inventor
Jeffrey A. Robl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0894003A1 publication Critical patent/EP0894003A1/fr
Publication of EP0894003A4 publication Critical patent/EP0894003A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention is directed to novel compounds possessing angiotensin converting enzyme (ACE) inhibitory activity and/or neutral endopeptidase (NEP) inhibitory activity and methods of preparing such compounds.
  • ACE angiotensin converting enzyme
  • NEP neutral endopeptidase
  • This invention is also directed to pharmaceutical compositions containing such ACE and/or NEP inhibiting compounds or pharmaceutically acceptable salts thereof and the method of using such compositions.
  • R is H, alkyl, alkenyl, aryl- (CH 2 ) p -, heteroaryl- (CH2) P -, cycloheteroalkyl- (CH2) p -, or
  • R can be joined together with the carbon to which it is attached to form a 3 to 7 membered ring which may optionally be fused to a benzene ring;
  • R 1 is H or -COR 2 where R 2 is alkyl, aryl- (CH2) P -, cycloheteroalkyl- (CH 2 ) P -, heteroaryl- (CH 2 ) P -, alkoxy, or cycloalkyl- (CH 2 ) p -;
  • p is 0 or an integer from 1 to 8; and
  • ' A is a dipeptide derived from one or two non-proteinogenic amino acid or is a conformationally restricted dipeptide mimic as described below.
  • A is a dipeptide derivative of the structure where R la , R lb , R 2a and R 2b are independently selected from H, alkyl, aryl- (CH 2 ) p -, cycloalkyl, cycloheteroalkyl- (CH 2 ) P -, heteroaryl- (CH2) p -, biphenylmethyl, or
  • R la and R lb or R 2a and R 2b may be joined together to the carbon to which they are attached to form a 3 to 7 membered ring, optionally fused to
  • a benzene optional 5 or 6 membered ring containing a single hetero atom and which may optionally include an R 5 substituent (as shown) which is H, alkyl, aryl- (CH 2 ) P or cycloalkyl- (CH 2 ) P , cycloheteroalkyl- (CH 2 ) P , or cycloheteroaryl- (CH 2 > p -;
  • R 3 is H, alkyl or aryl -(CH2)p-;
  • R 4 is OH, Oalkyl, 0- (CH 2 ) p aryl- or NR ⁇ (R 2 ) where Ri and R 2 are independently H, alkyl, or aryl(CH2) p or heteroaryl- (CH2) p -; with the proviso that in A(l) at least one of
  • ⁇ -amino acid is other than a natural ⁇ -amino acid, and thus must be other than valine, leucine, phenylalanine, tyrosine, serine, cysteine, threonine, methionine, aspartic acid, glutamic acid, arginine, lysine or proline.
  • A can be a conformationally restricted dipeptide mimic which has the structure and is a non-proteinogenic dipeptide.
  • formationally restricted dipeptide mimic refers to a structural skeleton which has the attributes of a conventional dipeptide
  • Examples of the A(2) dipeptide mimics include any of the conformationally restricted dipeptide mimics set out below. CH 2 orS(O) 0 i 2
  • R 11 and R 12 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl -(CH2)m _ ⁇ aryl -(CH2)m _ - substituted aryl -(CH2)m-» and heteroaryl -(CH2)m _ - or R 11 and
  • R 12 taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons, or R 11 and R 12 taken together with the carbon to which they are attached complete a keto substituent, i.e., ⁇
  • R 8 , R 9 and R 7 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl -(CH2)m ⁇ - aryl- (CH2)m ⁇ substituted aryl- (CH2)m _ - and heteroaryl- (CH2)rrr;
  • RlO and R ⁇ are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl -(CH2)m-/ aryl- (CH2)rrw substituted aryl -(CH2)m ⁇ / an ⁇ 3 heteroaryl- (CH2)m- ⁇ o ⁇ R 6 and R 10 taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons, R ⁇ and R 8 taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons, or R 9 and R 10 taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons; m is zero or an integer from 1 to 6; R 4 is OH, Oalkyl, O- (CH 2 ) m -heteroaryl,
  • Ri and R 2 are independently H, alkyl, aryl(CH 2 ) p , aryl or heteroaryl,-
  • R.14 is hydrogen, lower alkyl, cycloalkyl, or phenyl
  • R 1 ⁇ is hydrogen, lower alkyl, lower alkoxy or phenyl
  • R 16 is alkyl or ary1- (CH2)m- • an ⁇ -
  • R ⁇ - 7 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl- (CH2)m-» aryl- (CH2)m-/ substituted aryl- (CH2)m _ - or heteroaryl- ( CH2 ) m- •
  • R 18 is H, alkyl or alkenyl, and R 18 and R 17 may be taken together with the carbon and nitrogen to which they are attached to complete a saturated N-containing ring of 5 or 6 ring members.
  • R 19 is H or an alkyl, and in A(4), R 19 and X (which is CH 2 ) together with the carbons to which they are attached may form an aromatic ring of carbons (as in A(15) .
  • the starting compounds H-A(l) and H-A(2) are described in the literature or are obtained by modifications of known procedures.
  • the starting compounds of formula H-A(l) or H-A(2) wherein A(l) or A(2) is as defined in formulas A(5-), A(13), A(16), A(21), where Y (where present) is CH 2 are disclosed by Thorsett et al., J. Med. Chem., 29_, p. 251 - 260 (1988), Harris et al. in U.S. Patents 4,587,050, 4,587,238, 4,629,787 and Yanagisawa et al. in U.S. Patent 4,734,410.
  • the starting compounds of formula H-A(l) or H-A ⁇ 2) wherein A(l) or A(2) is as defined in formula A(16) can be prepared by reduction of the corresponding starting compounds wherein A(l) or A(2) is as defined in formula A(3) .
  • H-A(2) wherein A(l) or A(2) is as defined in formula A(10) and Y is S, -SO, or -S ⁇ 2 are disclosed by Harris et al. and Patchett et al. in
  • H-A(2) wherein A ⁇ 1) or A(2) is as defined in formula A(12) are disclosed by Huang et al. in U.S.
  • Patent 4,465,679. The starting compounds of formula H-A(l) or
  • a pharmaceutical composition which includes a therapeutically effective amount of compound I and a pharmaceutically acceptable carrier therefor.
  • the pharmaceutical composition as defined above will be useful in the treatment of cardiovascular diseases such as hypertension and/or congestive heart failure.
  • a method for treating a cardiovascular disease such as hypertension and/or congestive heart failure, as well as other diseases as set out hereinafter, which includes the step of administering to a mammalian species, including humans, dogs and cats, a therapeutically effective amount of a composition as defined above.
  • alkyl or “lower alkyl” refers to straight or branched chain radicals having up to and including ten carbon atoms, preferably up to and including six carbon atoms, which may optionally include one, two, or three substituents including a hydroxy, amino, alkyl, cycloalkyl, aryl, halo, trifluoromethyl, cyano, -NH(lower alkyl), -N(lower alkyl) 2 , lower alkoxy, lower alkylthio, carboxy or heteroaryl.
  • alkenyl refers to straight or branched chain radicals of 3 to 10 carbon atoms having one or two double bonds, preferably straight chain radicals of 3 to 5 carbons having one double bond, which may optionally be substituted with one, two or three substituents including alkyl, aryl, cycloalkyl, hydroxy, amino, halo, trifluoromethyl, cyano, -NH(lower alkyl), -N(lower alkyl)2, lower alkoxy, lower alkylthio, carboxy or heteroaryl.
  • alkoxy or "lower alkoxy" and
  • alkylthio or “lower alkylthio” refer to such alkyl groups as defined above attached to an oxygen or sulfur.
  • cycloalkyl refers to saturated rings of 3 to 7 carbon atoms.
  • halo refers to chloro, bromo, fluoro, and iodo.
  • aryl refers to aromatic groups containing 6 to 10 carbons, preferably phenyl, 1- naphthyl, and 2-naphthyl, which may optionally contain one, two or three substituents selected from alkyl, alkoxy, alkylthio, halo, hydroxy, trifluoromethyl, -SO 2 NH 2 , amino, -NH(lower alkyl), or -N(lower alkyl) 2 , di- and tri-substituted phenyl, 1-naphthyl, or 2-naphthyl, wherein said substituents are preferably selected from methyl, methoxy, methylthio, halo, hydroxy, and amino.
  • heteroaryl refers to unsaturated rings of 5 or 6 atoms containing one or two O and S atoms and/or one to four N atoms provided that the total number of hetero atoms in the ring is 4 or less, which may optionally be substituted with one, two or three substituents which include alkyl, aryl, cycloalkyl, alkoxy or halo.
  • the heteroaryl ring is attached by way of an available carbon or nitrogen atom.
  • Preferred heteroaryl groups include 2-, 3-, or 4-pyridyl, 4-imidazolyl, 4-thiazolyl, 2- and 3-thienyl, and 2- and 3-furyl.
  • heteroaryl also includes bicyclic rings wherein the five or six membered ring containing 0, S, and N atoms as defined above is fused to a benzene or pyridyl ring.
  • Preferred bicyclic rings are 2- and 3-indolyl and 4- and 5-quinolinyl .
  • the mono or bicyclic heteroaryl ring can also be additionally substituted at an available carbon atom by a lower alkyl, halo, hydroxy, benzyl, or cyclohexylmethyl.
  • the mono or bicyclic ring has an available N-atom such N atom can also be substituted by an N- protecting group such as
  • the compounds of formula I of the invention may be prepared as outlined in Reaction Scheme I set out below (where x is 0 or 1) .
  • acid 2 may be reacted with a suitably O-protected (e.g. PG 1 is benzyl, p- methoxybenzyl, tetrahydropyranyl, trityl, benzhydryl, etc.) hydroxylamine to give the adduct 3.
  • PG 1 is benzyl, p- methoxybenzyl, tetrahydropyranyl, trityl, benzhydryl, etc.
  • PG 1 is benzyl, p- methoxybenzyl, tetrahydropyranyl, trityl, benzhydryl, etc.
  • compound 3 may be formylated with an formylating agent 4a to give acid compound 7.
  • This acid may be coupled with A(l) or A(2) directly or optically resolved to give 7* and then coupled to give compound 5.
  • Compound 5 is then converted to compound of the invention IA as describedabove.
  • the compounds of formula I of the invention contain one or more asymmetric centers. Thus, these compounds can exist in diastereoisomeric forms or in mixtures thereof and all of such forms are within the scope of this invention.
  • the above described processes can utilize racemates, enantiomers, or diastereomers as starting materials. When diastereomeric compounds are prepared, they can be separated by conventional chromatographic or fractional crystallization methods.
  • the compounds of formula I of the invention can be isolated in the form of a pharmaceutically acceptable salt.
  • Suitable salts for this purpose are alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, and salts derived from amino acids such as arginine, lysine, etc. These salts are obtained by reacting the acid form of the compound with an equivalent of base supplying the desired ion in a medium in which the salt precipitates or in aqueous medium and then lyophilizing.
  • the compounds of formula I of the invention are inhibitors of angiotensin converting enzyme and/or neutral endopeptidase.
  • the compounds of formula I including their pharmaceutically acceptable salts are useful in the treatment of physiological conditions in which either angiotensin converting enzyme inhibitors or neutral endopeptidase inhibitors have been shown to be useful.
  • Such conditions include cardiovascular diseases, particularly, hypertension, congestive heart failure, renal failure, and hepatic cirrhosis, as well as analgesic activity.
  • the compounds of formula I are also inhibitors of other metalloproteases such as the matrix metalloproteases, for example, gelatinase, collagenase and stromylysin and thus are useful in the treatment of osteroarthritis, rheumatoid arthritis, metastatic tumors, and angiogenesis.
  • Diuresis, natriuresis, and blood pressure reduction are produced in a mammalian host such as man by the administration of from about 1 mg. to about 100 mg. per kg. of body weight per day, preferably from about 1 mg. to about 50 mg. per kg. of body weight per day, of one or more of the compounds of formula I or a pharmaceutically acceptable salt thereof.
  • the compounds of formula I are preferably administered orally, but parenteral routes such as subcutaneous, intramuscular, and intravenous can also be employed.
  • the daily dose can be administered singly or can be divided into two to four doses administered throughout the day.
  • the ACE and/or NEP inhibitors of formula I can be administered in combination with human ANF 99 - 126. Such combination would contain the inhibitor of formula I at from about 1 to about 100 mg. per kg. of body weight and the human ANF 99 - 126 at from about 0.001 to about 0.1 mg. per kg. of body weight.
  • the ACE and/or NEP inhibitors of formula I can be administered in combination with other classes of pharmaceutically active compounds.
  • a calcium channel blocker for example, a calcium channel blocker, a potassium channel activator, a cholesterol reducing agent, etc.
  • ACE and/or NEP inhibitors of formula I or a pharmaceutically acceptable salt thereof and other pharmaceutically acceptable ingredients can be formulated for the above described pharmacetical uses .
  • suitable compositions for oral administration include tablets, capsules, and elixirs
  • suitable compositions for parenteral administration include sterile solutions and suspensions.
  • About 10 to 500 mg. of active ingredient is compounded with physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavoring, etc., in a unit dose form as called for by accepted pharmaceutical practice.
  • Preferred compounds of the invention are those of formula I wherein R 1 is H, x is 1, R is alkyl or arylalkyl, and A is A(l) , preferably
  • R la and R lb are each independently alkyl such as methyl or ethyl, or arylalkyl such as benzyl, or
  • R la and R lb together with the carbon to which they are attached form a 3-7 membered ring, preferably a 5-membered ring, or R la and/or R lb is biphenylmethylene and the other may be H.
  • A(l) preferably where non- proteino-genic amino acid where R 3 is H, alkyl, such as methyl or ethyl, aryl such as phenyl, or arylalkyl, such as benzyl,
  • R 2a and R 2b are independently selected from
  • 3-7 membered ring preferably 5- or 6-membered ring.
  • the aqueous phase was brought to pH 1.0 with 6 N_ HCI (70 ml) , extracted with EtOAc (3 x 500 ml) and the combined organic extracts were washed with brine (100 ml), dried (anhydrous Na2S ⁇ 4) , filtered, evaporated to dryness and dried in vacuo .
  • the crude product mixture was chromatographed on a silica gel column (Merck) , eluting the column with CH2Cl2:CH3 ⁇ H:HOAc (100:5:0.2) to give title compound as a thick yellow syrup (27.222 g, 70.7%) with consistent ⁇ H-MMR and 13 C-NMR spectral data.
  • TLC Rf 0.27 (Silica gel; CH2CI2 :CH3 ⁇ H:HOAc- 100:5:0.5; UV, PMA) .
  • Part A(2) compound (16.69 g, 56.3 mmoles) in dry dimethyformamide (121 ml) was treated with l-ethyl-3- (3-dimethylaminopropy1) - carbodiimide (10.64 g, 55.5 mmoles) and stirred at room temperature for 3.0 hours.
  • the reaction mixture was partitioned between EtOAc (2 x 492 ml) and 1.0 N NaHC ⁇ 3 (492 ml), and the combined organic extracts were washed with H2O (3 x 492 ml) , brine (492 ml), dried (anhydrous MgS ⁇ 4), filtered, evaporated to dryness and dried in vacuo.
  • Example 1 Part E Isomers A and B (1:1 mixture of diastereomers, 535 mg, 0.87 mmol) in MeOH (10 mL) was hydrogenated (balloon) over 10% Pd/C (123 mg) at room temperature for 2.75 hours. The solvent was filtered through Celite and the filtrate was stripped to give a diastereomeric mixture of Isomers A and B. Trituration of a solution of the residue in MeOH with Et 2 ⁇ provided 350 mg of the diastereomeric mixture.
  • the aqueous layer was extracted with CH 2 C1 2 (2x700 ml) .
  • the CH 2 C1 2 extracts were combined, washed with brine, dried over anhydrous Mg 2 S ⁇ 4 and evaporated in vacuo.
  • the black residue was passed through a pad of silica gel (E. Merck, 230-400 mesh, 900 g) eluting with EtOAc-hexane (1:1) to afford a tic-homogeneous title compound (144.8 g) as a yellow oil in 93% in yield.
  • Part B(7) compound (124.8 g, 296.81 mmole) and 10% Pd/C (32g) in dry DMF (2.0 L) was hydrogenated for 24 hours. After completion, argon was bubbled through the reaction mixture to remove excess hydrogen and methyl sulfide (2.6 ml) was added to poison the palladium.
  • 1-hydroxybenzotriazole hydrate 46.74 g
  • ethyl-3 (3-dimethylamino) - propylcarbodiimide hydrochloride salt (68.74 g) .
  • the resulting solution was stirred at room temperature under argon for 3.5 hours, diluted with EtOAc (2 L) and filtered through a pad of celite.
  • Part A compound (641 mg, 1.42 mmol) was partitioned between EtOAc and 5% KH 2 PO 4 (adjusted to pH 2.5 with H 3 PO 4 ) . The layers were separated and the aqueous layer was back-extracted with EtOAc. The pooled EtOAc extracts were washed with brine, dried (Na 2 S ⁇ 4) , filtered and stripped to give an oil (assume 1.42 mg) . The oil was dissolved in CH 2 CI 2 (10 mL) and the resulting solution was treated with Part B amine (364 mg, 1.50 mmol) in CH 2 C1 2 (2 mL) and cooled to 0°C.
  • Acetic anhydride 500 ⁇ L was added to formic acid (5.0 mL) at 0°C and the mixture was stirred for 30 minutes. Approximately 2.6 mL of this solution was added to a solution of Part C compound (208 mg, 0.413 mmol) in THF (1.1 mL) at 0°C. After 30 minutes, most of the solvent was removed by rotary evaporation and the residue was partitioned between EtOAc and saturated NaHC0 3 . The EtOAc extract was washed with brine, dried (Na 2 S ⁇ 4 ) , filtered and stripped to give title compound (216 mg, 97%) as an oily foam which was used directly in the next reaction without futher purification.
  • Part D compound 216 mg, 0.402 mmol
  • absolute EtOH 5 mL
  • Pd/C 33 mg
  • the mixture was filtered through Celite, stripped, and azeotroped twice with EtOAc/Et 2 ⁇ /hexanes to give title compound (174 mg, 97%) as an off-white foam.
  • Solid sodium azide (26.0 g., 0.2 mole) was introduced into a 3-neck round-bottom flask with an overhead stirrer, made into a paste with warm water (26 ml), layered with chloroform (160 ml) and cooled down to 0° (ice-salt bath) .
  • the mixture was treated dropwise with concentrated sulfuric acid (11.2 ml, 0.5 eq.) over a period of 10 minutes, stirred for an additional 10 minutes then decanted into a flask containing anhydrous sodium sulfate.
  • the dried solution was filtered through a glass wool plug in a funnel into a 500-ml round-bottom flask. Titration of an aliquot (1.0 ml) with 1.0 N NaOH using phenolphthalein as an indicator gave a normalitity of 1.7 N for the hydrazoic acid.
  • Tetralone (15.94 g, 0.108 mole) was added to the hydrazoic acid solution (0.136 mole or 1.25 eq. ) , heated to 40-45° (oil bath) then treated dropwise with 36.0 N H2SO4 (28.7 ml, 5 eq. ) over a period of 1.0 hour. (Intense bubbling took place with each drop added for the first 30 minutes) . The reaction mixture was cooled down to room temperature, poured into H2O (720 ml) and stirred for 5 minutes.
  • Part A(3) compound (10.858 g, 53.7 mmoles) in dry tetrahydrofuran (100 ml) was treated with Bu4NBr (1.791 g, 5.56 mmoles) and powdered KOH (3.937 g, 70.2 mmoles) followed by ethyl bromoacetate (6.8 ml, 61.3 mmoles).
  • the reaction mixture was stirred at room temperature under argon for 1.5 hours then partitioned between H20 (196 ml) and CH2CI2 (2 x 375 ml) .
  • Part A(4) compound (8.95 g, 31.0 mmoles) in absolute ethanol (50 ml) was treated with 10% Pd/C (443 mg) and hydrogenated at 45 psi for 3.5 hours, venting the Parr bottle every 30 minutes for the first 1.5 hours.
  • the mixture was filtered through a Celite ® pad in a millipore unit, washing the pad well with absolute ethanol (3 x 50 ml) .
  • the clear filtrate was evaporated to dryness and dried in vacuo to give title compound as a thick yellow syrup (7.929 g, 97.5%) with consistent 1 H-NMR and 13 C-NMR spectral data.
  • TLC Rf 0.45 (Silica gel; CH2CI2 :CH3 ⁇ H- 9:1; UV) .
  • Example 3 Part A ephedrine salt (414 mg, 0.93 mmole), was partitioned between 5 % KH2PO4 (adjusted to pH 2.5; 4.0 ml) and EtOAc ( 2 x 20 ml) and the combined organic extracts were washed with brine (4.0 ml), dried (anhydrous Na2S ⁇ 4) , filtered, evaporated to dryness and dried in vacuo to give the free acid of the Example 4 Part A compound as a clear syrup (286.6 mg, 100 % crude yield) .
  • Part D compound 256.7 mg
  • CH3OH 3.5 ml
  • 1.0 N NaOH 2.17 ml, 4 eq
  • the reaction mixture was brought to pH 1.0 with 5% KHSO4 (9.45 ml), extracted with EtOAc (40 ml) and the organic extract washed with brine (5.0 ml), dried (anhydrous Na2S ⁇ 4) , filtered, evaporated to dryness and dried in vacuo .
  • the reaction mixture was partitioned between EtOAc (2 x 200 ml) and H2O (60 ml) and the combined organic extracts were washed sequentially with 0.5 N. HCI (60 ml), H2O (60 ml), 1/2 saturated NaHC03 (60 ml) and brine (60 ml), dried (anhydrous Na2S04), filtered, evaporated to dryness and dried in vacuo .
  • the crude product mixture was chromatographed on a silica gel column (Merck, 200 g) , eluting the column with EtOAc to give the desired product as a syrup (4.0 g) .
  • reaction mixture was stirred at -78°C for 5.0 minutes, allowed to come to room temperature over a period of 45 minutes, then partitioned between EtOAc (200 ml) and 0.5 N HCI (2 x 20 ml) . The organic phase was washed with brine (40 ml) , dried (anhydrous
  • Part D compound 1.238 g, 3.06 mmoles
  • dry DMF 3.5 ml
  • benzyl bromide 0.35 ml, 2.94 mmoles
  • CS2CO3 450 mg, 1.38 mmoles
  • the mixture was diluted with EtOAc (50 ml) , washed with H2O (5.0 ml), 0.5 N HCI (5.0 ml) and brine (5.0 ml) , dried (anhydrous Na2 ⁇ 4) , filtered, evaporated to dryness and dried in vacuo .
  • Part E compound (586 mg, 1.18 mmoles) in dry methanol (15 ml) was treated with NH2NH2»H2 ⁇ (66 ⁇ l, 1.2 eq) and stirred at room temperature for 48 hours.
  • the reaction mixture was diluted with Et2 ⁇ (50 ml) and filtered through a millipore unit, washing the solids well with Et2 ⁇ (40 ml) .
  • the clear solution was evaporated to dryness and the solids obtained were suspended in CH2CI2 (90 ml) and the solution filtered through a millipore unit, washing the solids well with CH2CI2 (40 ml) .
  • Example 3 Part A ephedrine salt (538 mg, 1.2 mmoles), was partitioned between 5% KH2PO4
  • Part H compound (535 mg, 0.78 mmole) in CH3OH (15 ml) was treated with 10 % Pd/C
  • TLC Rf 0.38 (Silica gel; CH2Cl2:MeOH- 9:1; UV) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des n-formyl hydroxylamines représentés par la structure (I). R et R1 sont conformes à la description qui en est donnée dans la demande, et A est un dipeptide dérivé d'un acide aminé ou est un dipeptide mimique à conformation restreinte.
EP97917889A 1996-04-12 1997-04-07 Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep Withdrawn EP0894003A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1629596P 1996-04-12 1996-04-12
US16295P 1996-04-12
PCT/US1997/005744 WO1997038705A1 (fr) 1996-04-12 1997-04-07 Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep

Publications (2)

Publication Number Publication Date
EP0894003A1 true EP0894003A1 (fr) 1999-02-03
EP0894003A4 EP0894003A4 (fr) 2000-10-04

Family

ID=21776392

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97917889A Withdrawn EP0894003A4 (fr) 1996-04-12 1997-04-07 Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep

Country Status (5)

Country Link
EP (1) EP0894003A4 (fr)
JP (1) JP2000511882A (fr)
AU (1) AU715451B2 (fr)
CA (1) CA2251292A1 (fr)
WO (1) WO1997038705A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
CA2320476A1 (fr) 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Agents antibacteriens
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9827805D0 (en) 1998-12-16 1999-02-10 British Biotech Pharm Antibacterial agents
GB9907055D0 (en) * 1999-03-29 1999-05-19 British Biotech Pharm Antibacterial agents
ES2242411T3 (es) * 1999-08-10 2005-11-01 Vernalis (Oxford) Ltd Agentes antibacterianos.
US6509330B2 (en) 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
DE10020818A1 (de) * 2000-04-28 2001-10-31 Degussa 2,6-Diamino-6-methyl-heptansäure und Derivate, Verfahren zu deren Herstellung und deren Verwendung
KR102055491B1 (ko) * 2015-05-22 2019-12-12 바이오테릭스, 인코포레이티드 단백질을 표적하는 화합물, 조성물, 방법, 및 그의 용도
WO2017201069A1 (fr) 2016-05-18 2017-11-23 Biotheryx, Inc. Dérivés d'oxoindoline utilisés comme modulateurs de la fonction protéique
AU2018236286B2 (en) * 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236872A2 (fr) * 1986-03-11 1987-09-16 F. Hoffmann-La Roche Ag Dérivés hydroxylamine, leur préparation et emploi comme médicaments
EP0524553A1 (fr) * 1991-07-23 1993-01-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Acylmercaptoalcanoyldipeptides, procédés de leur préparation et leur utilisation thérapeutique
EP0599444A1 (fr) * 1992-05-18 1994-06-01 E.R. SQUIBB & SONS, INC. Inhibiteurs à double effet
EP0655461A1 (fr) * 1993-11-16 1995-05-31 Ciba-Geigy Ag Dérivés d'amino acide cycliques ayant une activité inhibante d'ACE et NEP

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539150A (en) * 1983-06-29 1985-09-03 Mitsui Toatsu Chemicals, Inc. Benzothiazepine derivatives and their methods of preparation
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236872A2 (fr) * 1986-03-11 1987-09-16 F. Hoffmann-La Roche Ag Dérivés hydroxylamine, leur préparation et emploi comme médicaments
EP0524553A1 (fr) * 1991-07-23 1993-01-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Acylmercaptoalcanoyldipeptides, procédés de leur préparation et leur utilisation thérapeutique
EP0599444A1 (fr) * 1992-05-18 1994-06-01 E.R. SQUIBB & SONS, INC. Inhibiteurs à double effet
EP0655461A1 (fr) * 1993-11-16 1995-05-31 Ciba-Geigy Ag Dérivés d'amino acide cycliques ayant une activité inhibante d'ACE et NEP

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOURNIE-ZALUSKI M -C ET AL: "NEW BIDENTATES AS FULL INHIBITORS OF ENKEPHALIN-DEGRADING ENZYMES: SYNTHESIS AND ANALGESIC PROPERTIES" JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 28, no. 9, 1985, pages 1158-1169, XP000906979 ISSN: 0022-2623 *
NISHINO E.A.: "DESIGN OF POTENT REVERSIBLE INHIBITORS OF THERMOLYSIN. PEPTIDES CONTAINING ZINC COORDINATING LIGANDS AND THEIR USE IN AFFINITY CHROMATOGRAPHY" BIOCHEMISTRY, vol. 18, no. 20, 1979, pages 4340-4347, XP002144002 EASTON, PA US *
See also references of WO9738705A1 *
WELLER E.A.: "Design of conformationally constrained angiotensin-converting-enzyme inhibitors" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 125, no. 1, 1984, pages 82-89, XP000915405 ORLANDO, FL US *

Also Published As

Publication number Publication date
WO1997038705A1 (fr) 1997-10-23
AU2609497A (en) 1997-11-07
EP0894003A4 (fr) 2000-10-04
JP2000511882A (ja) 2000-09-12
AU715451B2 (en) 2000-02-03
CA2251292A1 (fr) 1997-10-23

Similar Documents

Publication Publication Date Title
EP0119954B1 (fr) Acides 3-amino-1-benzazépine-2-one-1-alkanoiques, leur procédé de préparation, les préparations pharmaceutiques les contenant de même que leur emploi thérapeutique
EP0236872B1 (fr) Dérivés hydroxylamine, leur préparation et emploi comme médicaments
EP0184550B1 (fr) Dérivés de 5-amino-4-hydroxy valérylamides
US4820729A (en) N-substituted-amido-amino acids
US4350704A (en) Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
CA1196636A (fr) Benzazepin-2-ones
WO1997038705A1 (fr) Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep
EP0119161B1 (fr) Dérivés de benzazocinone et benzazoninon, leur procédé de préparation, préparations pharmaceutiques contenant ces composés, et leur application thérapeutique
EP0037231A2 (fr) Dérivés acylés de l'acide octahydro-1H-indole-carboxylique-2
HU209413B (en) Method for producing 2-azabicyclo [3.1.0] hexane-3-carboxylic acid derivatives as well as their physiologically acceptable salts
EP0320118A2 (fr) Peptides à activité inhibant la collagénase
HU183652B (en) Process for preparing bicyclic compounds
EP0218688B1 (fr) Inhibiteurs de renine a substitution dihalo-statine
US4425355A (en) Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
EP0110224A2 (fr) Composés benzoylthio, leur préparation et emploi comme médicaments
EP0500989B1 (fr) Agents antihypertensifs dipeptidiques N-(pyridyl-alpha-substituée) carbonyle
JPS6319506B2 (fr)
WO1997038008A1 (fr) Derives d'amino-4-oxa-1-azabicyclo [3,2,0] heptan-7-one 6-substituee, inhibiteurs de la cysteine protease
US4490386A (en) Phosphate salts of 1-[2-[(1-alkoxycarbonyl-3-aralkyl)-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof
DE60014029T2 (de) Tripeptidische verbindungen mit wirksamkeit als selektive inhibitoren der aminopeptidase a und sie enthaltende pharmazeutische zusammensetzungen
US6777550B1 (en) N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
US4293481A (en) Tripeptide inhibitors of angiotensin-converting enzyme
KR890000769B1 (ko) 프롤린 유도체의 제법
HU187808B (en) Process for the preparation of n-bracket-carboxy-alkyl-bracket-prolina containing tripeptides
EP0059966B1 (fr) Analogues et dérivés de l'acide thiazolidine carboxylique substitué, comme antihypertenseurs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981005

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/05 A, 7C 07K 5/02 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000818

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030602

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060725